Correlation Between Initial Urine V-ATPase and Pathological Changes in IgA Nephropathy: Implications for Short-Term Outcomes

DOI: https://doi.org/10.62517/jmhs.202405315

Author(s)

Lin Hu, Liang Peng*

Affiliation(s)

Department of Nephrology, Loudi Central hospital of Hunan Province, Loudi, China *Corresponding author.

Abstract

This study aimed to investigate the alterations in expression and clinical relevance of ATP6V1A and ATP6V1E1 in urine samples from patients with IgA nephropathy(IgAN). The research included a cohort of 55 patients diagnosed with IgAN and a control group of 30 healthy individuals, with no significant differences in age or gender between the groups. The maximum tolerated dose of angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor antagonists(ARB) was used for 6 months. Treatment effectiveness was defined as a reduction in urinary protein of more than 50% from baseline. The results demonstrated that the urinary expression levels of ATP6V1A and ATP6V1E1 in patients with IgAN were significantly lower than those observed in the healthy control group. And in IgAN group, the expression of ATP6V1A in urine was significantly lower in patients with Tubular atrophy and interstitial fibrosis. Patients with IgAN were divided into low expression group and high expression group according to the median urinary levels of ATP6V1A and ATP6V1E1, and there was no significant difference in baseline proteinuria between the two groups. ATP6V1A Low-expression groups showed significantly higher proteinuria levels after 6 months of treatment compared to high-expression groups, as well as notably lower treatment efficacy. However, the two ATP6V1E1 groups did not differ significantly in either proteinuria levels or treatment efficacy at 6 months. Accordingly, urinary ATP6V1A may be a useful biomarker for detecting disease severity and therapeutic response in patients with IgAN.

Keywords

V-ATPase; IgA Nephropathy; Proteinuria; ACEI; ARB

References

[1]Heather N, R., et al., Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol, 2007. 18(12). [2] Eleni, S., et al., IgA nephropathy. Nat Rev Dis Primers, 2023. 9(1). [3]Pamela, S., Golgi glycosylation. Cold Spring Harb Perspect Biol, 2011. 3(4). [4] Anna, F., et al., The Close Relationship between the Golgi Trafficking Machinery and Protein Glycosylation. Cells, 2020. 9(12). [5]Yusuke, M., et al., GPHR is a novel anion channel critical for acidification and functions of the Golgi apparatus. Nat Cell Biol, 2008. 10(10). [6] Chang, W., et al., Loss of the Golgi Matrix Protein 130 Cause Aberrant IgA1 Glycosylation in IgA Nephropathy. Am J Nephrol, 2019. 49(4). [7]Connie, M., W. Samuel, and K. Patricia M, Human V-ATPase a-subunit isoforms bind specifically to distinct phosphoinositide phospholipids. J Biol Chem, 2023. 299(12). [8]Tim, V.D., et al., Mutations in ATP6V1E1 or ATP6V1A Cause Autosomal-Recessive Cutis Laxa. Am J Hum Genet, 2020. 107(2). [9] Soumita, B., et al., Supportive Management of IgA Nephropathy With Renin-Angiotensin Blockade, the AIIMS Primary IgA Nephropathy Cohort (APPROACH) Study. Kidney Int Rep, 2021. 6(6). [10]Maureen, B., et al., Prevalence of kidney failure in adults diagnosed with hereditary tubulopathies. J Nephrol, 2024(0). [11] Ri-Cong, X., et al., A mixed-method evaluation of the relationship between Oxford classification scores and longitudinal changes in proteinuria in patients with immunoglobulin A nephropathy. Front Endocrinol (Lausanne), 2023. 13(0). [12]Erratum for Cannata Serio et al. Mutations in the V-ATPase assembly factor VMA21 cause a congenital disorder of glycosylation with autophagic liver disease. Hepatology (Baltimore, Md.), 2022. 75(3): p. 772. [13]Milada, S.H., et al., Aberrant O-glycosylation and anti-glycan antibodies in an autoimmune disease IgA nephropathy and breast adenocarcinoma. Cell Mol Life Sci, 2012. 70(5). [14]Nina, O., et al., Severe phenotype of ATP6AP1-CDG in two siblings with a novel mutation leading to a differential tissue-specific ATP6AP1 protein pattern, cellular oxidative stress and hepatic copper accumulation. J Inherit Metab Dis, 2020. 43(4). [15]Eric J R, J., et al., ATP6AP1 deficiency causes an immunodeficiency with hepatopathy, cognitive impairment and abnormal protein glycosylation. Nat Commun, 2016. 7(0). [16]Williams, S., et al., Aberrant glycosylation in schizophrenia: a review of 25 years of post-mortem brain studies. Molecular psychiatry, 2020. 25(12): p. 3198-3207. [17] Hitoshi, S., et al., IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1. J Clin Invest, 2008. 118(2).